Bradley Cooper will return as co-executive producer along with the renowned live-event producing team Done + Dusted, working again with the Stand Up To Cancer production team, after a successful partnership for the 2016 telecast.

“As someone whose family has been significantly touched by cancer, I am proud to again have the privilege of co-executive producing this year’s Stand Up To Cancer telecast,” said Cooper. “This show reminds everyone that you are never alone… that there is a community of support out there when you need it most. That’s the power of SU2C. Most importantly, the telecast showcases the significant progress being made in the fight against cancer, instilling hope in those facing the disease. This one-hour broadcast unites us all to raise funds for more effective treatments to save lives now.”

To date, more than $480 million has been pledged in support of SU2C’s innovative cancer research. The organization has brought together more than 1,500 of the best scientists from over 180 leading institutions with an emphasis on collaborative, multidisciplinary teams that deliver new therapies and treatments to cancer patients. Scientists work together on Stand Up To Cancer’s 24 signature “Dream Teams,” among a total of 79 team science grants and awards, whose research is aimed at ending cancer’s reign as a leading cause of death worldwide. SU2C-funded researchers have planned, launched or completed more than 180 clinical trials involving over 12,000 patients.

The results have been exceptional. In just under 10 years, SU2C research has contributed to FDA approval of five new cancer therapies, including treatments for breast, ovarian, and pancreatic cancers and difficult-to-treat leukemias. Additional trial results have been submitted or are nearing completion for breast, colon, ovarian, and prostate cancers and for metastatic melanoma. Stand Up To Cancer has provided substantial funding for the study of immunotherapy in the fight against cancer, and has advanced development of technologies using blood tests to identify cancers early, imaging to understand tumor progression, and precision medicine via new laboratory tools.

SU2C’s wide-ranging scientific portfolio is overseen by a blue-ribbon scientific advisory committee chaired by Nobel Prize winner Phillip A. Sharp, Ph.D., Institute Professor at the Massachusetts Institute of Technology. Most grants are administered by SU2C’s Scientific Partner, the American Association for Cancer Research (AACR), the world’s first and largest professional organization dedicated to advancing cancer research.

Tune in to this incredible event on Friday, September 7th from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT) on CBS, SHOWTIME and other networks.